Birgitta Versluijs

152 Supplemental data TABLE S4. Univariate/multivariate predictor analyses for Therapy Failure in Allo-LS Univariate analyses Hazard ratio (95% CI), P value RV from NPA or BAL at diagnosis Allo-LS 0.48 (0.19-1.18), p=0.11 Intensive care for mechanical ventilation 2.14 (0.96-4.79), p=0.06* Systemic GvHD treatment prior to Allo-LS 2.60 (0.97-6.99, p=0.06* Multivariate analyses Hazard ratio (95% CI), P value Systemic GvHD treatment prior to Allo-LS 2.63 (0.98-7.05), p=0.06 Intensive care for mechanical ventilation 2.15 (0.96-4.82), p=0.06 Allo-LS = Alloimmune mediated lung syndrome, IPS= Idiopathic Pneumonia Syndrome, BOS = Bronchiolitis Obliterans Syndrome, GvHD = Graft versus Host Disease, RV = Res- piratory Virus. * variables with p<0.1 in univariate analyses where included in multivariate analyses. TABLE S5. Univariate/multivariate predictor analyses for non relapse mortality in Allo-LS Univariate analyses Hazard ratio (95% CI), P value RV from NPA or BAL at diagnosis Allo-LS 0.25 (0.10-0.64), p=0.004* Intensive care for mechanical ventilation 3.20 (1.45-7.26), p=0.004* Systemic GvHD treatment prior to Allo-LS 1.87 (0.64-5.45), p=0.25 Multivariate analyses Hazard ratio (95% CI), P value RV from NPA or BAL at diagnosis Allo-LS 0.25 (0.10-0.65), p=0.004 Intensive care for mechanical ventilation 3.38 (1.34-8.54), p=0.01 Allo-LS = Alloimmune mediated lung syndrome, IPS= Idiopathic Pneumonia Syndrome, BOS = Bronchiolitis Obliterans Syndrome, GvHD = Graft versus Host Disease, RV = Res- piratory Virus. * variables with p<0.1 in univariate analyses where included in multivariate analyses. 8